162 related articles for article (PubMed ID: 16245282)
1. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
2. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
3. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Yen WC; Lamph WW
Mol Cancer Ther; 2005 May; 4(5):824-34. PubMed ID: 15897247
[TBL] [Abstract][Full Text] [Related]
4. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
6. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Tooker P; Yen WC; Ng SC; Negro-Vilar A; Hermann TW
Cancer Res; 2007 May; 67(9):4425-33. PubMed ID: 17483357
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Yen WC; Prudente RY; Lamph WW
Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
[TBL] [Abstract][Full Text] [Related]
8. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Fu J; Ding Y; Huang D; Li H; Chen X
Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
[TBL] [Abstract][Full Text] [Related]
9. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
10. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
11. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
16. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Klopper JP; Berenz A; Hays WR; Sharma V; Pugazhenthi U; Janssen J; Singh M; Bissonnette RP; Haugen BR
Clin Cancer Res; 2008 Jan; 14(2):589-96. PubMed ID: 18223235
[TBL] [Abstract][Full Text] [Related]
17. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
19. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
Rebbaa A; Chu F; Davis FB; Davis PJ; Mousa SA
Angiogenesis; 2008; 11(3):269-76. PubMed ID: 18386142
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Lee JT; Steelman LS; McCubrey JA
Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
